Management of rheumatic disease with comorbid HBV or HCV infection

Nature Reviews Rheumatology

Volumn 8, Issue 6, 2012, Pages 348-357

  Vassilopoulos, Dimitrios ^a   Calabrese, Leonard H ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; ETANERCEPT; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE LIVER FAILURE; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; APHERESIS; AUTOIMMUNE DISEASE; COMORBIDITY; CRYOGLOBULINEMIA; CYTOPENIA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; LYMPHOMA; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEROCONVERSION; VIREMIA; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; MALE; RHEUMATIC DISEASES; VIRUS ACTIVATION;

EID: 84861663197     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.63     Document Type: Review

References (90)

1. Lok, A. S. F. & McMahon, B. J. AASLD Practice Guidelines. Chronic hepatitis B: update 2009. American Association for the Study of Liver Disease [online], http://www.aasld.org/practiceguidelines/documents/ bookmarked%20practice%20guidelines/chronic-hep-b-update-2009%208-24-2009.pdf (2011).
2. Rosen, H. R. Clinical practice. Chronic hepatitis C infection. N. Engl. J. Med. 364, 2429-2438 (2011).
3. Dienstag, J. L. Hepatitis B virus infection. N. Engl. J. Med. 359, 1486-1500 (2008).
4. Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
5. Hatzakis, A. et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J. Viral Hepat. 18 (Suppl. 1), 1-16 (2011).
6. Liang, T. J. Hepatitis B: the virus and disease. Hepatology 49, S13-S21 (2009).
7. Chisari, F. V., Isogawa, M. & Wieland, S. F. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris) 58, 258-266 (2010).
8. Hosel, M. et al. Not interferon, but interleukin6 controls early gene expression in hepatitis B virus infection. Hepatology 50, 1773-1782 (2009).
9. Puro, R. & Schneider, R. J. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J. Virol. 81, 7351-7362 (2007). (Pubitemid 47047824)
10. Hadziyannis, S. J. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J. Hepatol. 55, 183-191 (2011).
11. McMahon, B. J. The natural history of chronic hepatitis B virus infection. Hepatology 49, S45-S55 (2009).
12. Hadziyannis, S. J. & Vassilopoulos, D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34, 617-624 (2001). (Pubitemid 32927983)
13. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009).
14. Chotiyaputta, W. & Lok, A. S. Endpoints of hepatitis B treatment. J. Viral Hepat. 17, 675-684 (2010).
15. Ayoub, W. S. & Keeffe, E. B. Review article: current antiviral therapy of chronic hepatitis B. Aliment. Pharmacol. Ther. 34, 1145-1158 (2011).
16. Heathcote, E. J. et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140, 132-143 (2011).
17. Hoofnagle, J. H. Reactivation of hepatitis B. Hepatology 49, S156-S165 (2009).
18. Perrillo, R. P. Acute Flares in Chronic Hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120, 1009-1022 (2001). (Pubitemid 32193199)
19. Calabrese, L. H., Zein, N. N. & Vassilopoulos, D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann. Rheum. Dis. 65, 983-989 (2006). (Pubitemid 44133258)
20. Calabrese, L. H., Zein, N. & Vassilopoulos, D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. 63 (Suppl. 2), ii18-ii24 (2004). (Pubitemid 39424653)
21. Cheng, A. L. et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37, 1320-1328 (2003).
22. Michel, M., Duvoux, C., Hezode, C. & Cherqui, D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J. Rheumatol. 30, 1624-1625 (2003). (Pubitemid 36835467)
23. Ostuni, P., Botsios, C., Punzi, L., Sfriso, P. & Todesco, S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis. 62, 686-687 (2003). (Pubitemid 36760576)
24. Perez-Alvarez, R. et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90, 359-371 (2011).
25. Winthrop, K. L. & Calabrese, L. H. Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann. Rheum. Dis. 70, 1701-1703 (2011).
26. Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22, 1170-1180 (2011).
27. Mendez-Navarro, J. et al. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int. 31, 330-339 (2011).
28. Chen, X. Q., Peng, J. W., Lin, G. N., Li, M. & Xia, Z. J. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large Bcell lymphoma undergoing prolonged rituximab therapy. Med. Oncol. http://dx.doi.org/10.1007/s120320119974-0.
29. Pyrpasopoulou, A. et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol. Int. 31, 403-404 (2011).
30. Vassilopoulos, D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur. J. Intern. Med. 22, 572-575 (2011).
31. Germanidis, G., Hytiroglou, P., Zakalka, M. & Settas, L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J. Hepatol. http://dx.doi.org/10.1016/j. jhep.2011.10.011.
32. Nagashima, T. & Minota, S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology. (Oxford) 47, 1838-1840 (2008).
33. Kishida, D. et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod. Rheumatol. 21, 215-218 (2011).
34. Tsuboi, H. et al. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. Mod. Rheumatol. 21, 701-705 (2011).
35. Raimondo, G. et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 49, 652-657 (2008).
36. Lok, A. S. et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100, 182-188 (1991).
37. Hui, C. K. et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131, 59-68 (2006).
38. Yeo, W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27, 605-611 (2009).
39. Matsue, K. et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive Bcell lymphoma. Cancer 116, 4769-4776 (2010).
40. Koo, Y. X. et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann. Hematol. 90, 1219-1223 (2011).
41. Niitsu, N., Hagiwara, Y., Tanae, K., Kohri, M. & Takahashi, N. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large Bcell lymphoma after rituximab combination chemotherapy. J. Clin. Oncol. 28, 5097-5100 (2010).
42. Charpin, C. et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res. Ther. 11, R179 (2009).
43. Caporali, R. et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res. (Hoboken) 62, 749-754 (2010).
44. Vassilopoulos, D. et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann. Rheum. Dis. 69, 1352-1355 (2010).
45. Lan, J. L. et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann. Rheum. Dis. 70, 1719-1725 (2011).
46. Loomba, R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519-528 (2008). (Pubitemid 351665421)
47. Katz, L. H., Fraser, A., Gafter-Gvili, A., Leibovici, L. & Tur-Kaspa, R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J. Viral Hepat. 15, 89-102 (2008).
48. Tsutsumi, Y. et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann. Hematol. 88, 375-377 (2009).
49. Pei, S. N. et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann. Hematol. 89, 255-262 (2010).
50. He, Y. F. et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann. Hematol. 87, 481-485 (2008).
51. Vassilopoulos, D. & Manolakopoulos, S. Rheumatic manifestations of hepatitis. Curr. Opin. Rheumatol. 22, 91-96 (2010).
52. Khasnis, A. A., Schoen, R. T. & Calabrese, L. H. Emerging viral infections in rheumatic diseases. Semin. Arthritis Rheum. 41, 236-246 (2011).
53. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne nonA, non- B viral hepatitis genome. Science 244, 359-362 (1989).
54. Rustgi, V. K. The epidemiology of hepatitis C infection in the United States. J. Gastroenterol. 42, 513-521 (2007). (Pubitemid 47190067)
55. Cornberg, M. et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 31 (Suppl. 2), 30-60 (2011).
56. Groom, H. et al. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J. Clin. Gastroenterol. 42, 97-106 (2008).
57. Gravitz, L. Introduction: a smouldering public-health crisis. Nature 474, S2-S4 (2011).
58. Lauer, G. M. & Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 345, 41-52 (2001). (Pubitemid 32634271)
59. Shire, N. J. et al. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV1coinfected patients with hemophilia. Hepatology 44, 1146-1157 (2006). (Pubitemid 44748366)
60. Saadoun, D., Landau, D. A., Calabrese, L. H. & Cacoub, P. P. Hepatitis Cassociated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 46, 1234-1242 (2007). (Pubitemid 47244492)
61. Manning, D. S. & Afdhal, N. H. Diagnosis and quantitation of fibrosis. Gastroenterology 134, 1670-1681 (2008). (Pubitemid 351615414)
62. Lai, M. & Afdhal, N. H. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am. J. Gastroenterol. 106, 2121-2122 (2011).
63. Ferri, C. et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig. Liver Dis. 39 (Suppl. 1), S13-S21 (2007). (Pubitemid 47541920)
64. Vassilopoulos, D. & Calabrese, L. H. Extrahepatic immunological complications of hepatitis C virus infection. AIDS 19 (Suppl. 3), S123-S127 (2005). (Pubitemid 41682179)
65. Ramos-Casals, M., Stone, J. H., Cid, M. C. & Bosch, X. The cryoglobulinaemias. Lancet 379, 348-360 (2012).
66. Zaja, F. et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum. 46, 2252-2254 (2002).
67. Zaja, F. et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101, 3827-3834 (2003). (Pubitemid 36857853)
68. Sansonno, D. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101, 3818-3826 (2003). (Pubitemid 36857852)
69. Saadoun, D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111, 5334-5341 (2008).
70. Cacoub, P., Delluc, A., Saadoun, D., Landau, D. A. & Sene, D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann. Rheum. Dis. 67, 283-287 (2008). (Pubitemid 351281259)
71. Quartuccio, L. et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45, 842-846 (2006). (Pubitemid 43985372)
72. Petrarca, A. et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 116, 335-342 (2010).
73. Dammacco, F. et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116, 343-353 (2010).
74. Sneller, M. C., Hu, Z. & Langford, C. A. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis Cassociated cryoglobulinemic vasculitis. Arthritis Rheum. 64, 835-842 (2012).
75. De Vita, S. et al. A randomized, controlled, trial of rituximab for treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 64, 843-853 (2012).
76. Pietrogrande, M. et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun. Rev. 10, 444-454 (2011).
77. Saadoun, D. et al. Rituximab plus Peginterferon?/ribavirin compared with Peginterferon?/ribavirin in hepatitis Crelated mixed cryoglobulinemia. Blood 116, 326-334 (2010).
78. Sene, D., Ghillani-Dalbin, P., Amoura, Z., Musset, L. & Cacoub, P. Rituximab may form a complex with IgM? mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 60, 3848-3855 (2009).
79. Saadoun, D. et al. Regulatory Tcell responses to low-dose interleukin2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067-2077 (2011).
80. De Vita S. Treatment of mixed cryoglobulinemia: a rheumatology perspective. Clin. Exp. Rheumatol. 29, S99-103 (2011).
81. Jensen, D. M. A new era of hepatitis C therapy begins. N. Engl. J. Med. 364, 1272-1274 (2011).
82. Cacoub, P. et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 52, 911-915 (2005). (Pubitemid 40365115)
83. Cid, M. C. et al. Interferon-alpha may exacerbate cryoblobulinemia- related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum. 42, 1051-1055 (1999). (Pubitemid 29215018)
84. Hoffman, W. P. & Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 8, 257-264 (2011).
85. Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762-784 (2008). (Pubitemid 351847559)
86. Brunasso, A. M., Puntoni, M., Gulia, A. & Massone, C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 50, 1700-1711 (2011).
87. Zein, N. N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol. 42, 315-322 (2005). (Pubitemid 40254244)
88. US National Library of Medicine. Infliximab treatment along with pegylated interferon and ribavirin in the treatment of hepatitis C (PARTNER). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00512278 (2011).
89. D'Amico, G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int. 54, 650-671 (1998).
90. Yim, H. J. & Lok, A. S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43, S173-S181 (2006).